Cited by 391Ovarian cancer diagnosis and treatmentEpigenetics and DNA MethylationMetal complexes synthesis and properties

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Epigenetic Resensitization to Platinum in Ovarian Cancer

Open access

Matei, Daniela, Fang, Fang, Shen, Changyu, Schilder, Jeanne, Arnold, Alesha, Zeng, Yan, Berry, William A., Huang, Tim, Nephew, Kenneth P.·2012·Cancer Research

DOI 10.1158/0008-5472.can-11-3909PMC PMC3700422

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Preclinical studies have shown that hypomethylating agents reverse platinum resistance in ovarian cancer. In this phase II clinical trial, based upon the results of our phase I dose defining study, we tested the clinical and biologic activity of low-dose decitabine administered before carboplatin in platinum-resistant ovarian cancer patients. Among 17 patients with heavily pretreated and platinum-resistant ovarian cancer, the regimen induced a 35% objective response rate (RR) and progression-free survival (PFS) of 10.2 months, with nine patients (53%) free of progression at 6 months. Global and gene-specific DNA demethylation was achieved in peripheral blood mononuclear cells and tumors. The number of demethylated genes was greater (P < 0.05) in tumor biopsies from patients with PFS more than 6 versus less than 6 months (311 vs. 244 genes). Pathways enriched at baseline in tumors from patients with PFS more than 6 months included cytokine–cytokine receptor interactions, drug transporters, and mitogen-activated protein kinase, toll-like receptor and Jak-STAT signaling pathways, whereas those enriched in demethylated genes after decitabine treatment included pathways involved in cancer, Wnt signaling, and apoptosis (P < 0.01). Demethylation of MLH1, RASSF1A, HOXA10, and HOXA11 in tumors positively correlated with PFS (P < 0.05). Together, the results of this study suggest that low-dose decitabine altered DNA methylation of genes and cancer pathways, restoring sensitivity to carboplatin in patients with heavily pretreated ovarian cancer and resulting in a high RR and prolonged PFS. Cancer Res; 72(9); 2197–205. ©2012 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-3909

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
The Epigenomics of Cancer
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
A systems biology approach for pathway level analysisPreprint
Drăghici, S., Khatri, P., Tarca, A. L., Amin, K., Done, A., Voichiţa, C., Georgescu, C., & Romero, R. J. (2007) · Genome Research · doi:10.1101/gr.6202607 · Cited by 1,263
Toll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Platinum Resistance: The Role of DNA Repair Pathways
Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 754
A cell biological view of Toll-like receptor function: regulation through compartmentalization
Barton, G. M., & Kagan, J. C. (2009) · Nature reviews. Immunology · doi:10.1038/nri2587 · Cited by 746
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Kantarjian, H. M., Oki, Y., Garcia‐Manero, G., Huang, X., O'Brien, S. M., Cortes, J. E., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z. E., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021162 · Cited by 684
DNA methylation analysis by pyrosequencing
Tost, J., & Gut, I. G. (2007) · Nature Protocols · doi:10.1038/nprot.2007.314 · Cited by 681

Show all 56 references

Sorted by citations

Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D. L., Böhm, S., Ahmed, A. A., Aspuria, P.-J. P., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S. P., Bookman, M. A., et al. (2015) · Nature reviews. Cancer · doi:10.1038/nrc4019 · Cited by 1,395
Self-citation
Epigenetic Determinants of CancerPreprint
Baylin, S. B., & Jones, P. A. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a019505 · Cited by 1,414
Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.028 · Cited by 1,199
Targeting the cancer epigenome for therapy
Jones, P. A., Issa, J. J., & Baylin, S. B. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.93 · Cited by 1,153
The challenge of drug resistance in cancer treatment: a current overview
Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9903-0 · Cited by 628
Epigenetic therapy in immune-oncology
Jones, P. A., Ohtani, H., Chakravarthy, A., & Carvalho, D. D. D. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0109-9 · Cited by 559
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozović, A., Gonçalves, A. C., Jurkovičová, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento‐Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 541
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 473
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Li, H., Chiappinelli, K. B., Guzzetta, A. A., Easwaran, H., Yen, R.-W. C., Vatapalli, R. J., Topper, M. J., Luo, J., Connolly, R. M., Azad, N. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1782 · Cited by 428
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 439
The future of epigenetic therapy in solid tumours—lessons from the past
Azad, N. S., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 346
Epigenetic therapy for ovarian cancer: promise and progress
Moufarrij, S., Dandapani, M., Arthofer, E., Gomez, S., Srivastava, A., Lopez-Acevedo, M., Villagra, A., & Chiappinelli, K. B. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0602-0 · Cited by 319
Combining Epigenetic and Immunotherapy to Combat Cancer
Chiappinelli, K. B., Zahnow, C. A., Ahuja, N., & Baylin, S. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2125 · Cited by 313
Metal-based drugs that break the rules
Allardyce, C. S., & Dyson, P. J. (2016) · Dalton Transactions · doi:10.1039/c5dt03919c · Cited by 309
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 310
Poised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
Chen, X., Chu, Q., Shi, Q., Zeng, Y., Lu, J., & Li, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02142-w · Cited by 347
Self-citation
Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden
Stone, M. L., Chiappinelli, K. B., Li, H., Murphy, L. M., Travers, M. E., Topper, M. J., Mathios, D., Lim, M. K., Shih, I., Wang, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712514114 · Cited by 297
NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer
Özeş, A., Miller, D. F., Özeş, O. N., Fang, F., Liu, Y., Matei, D. E., Huang, T. H. ‐., & Nephew, K. P. (2016) · Oncogene · doi:10.1038/onc.2016.75 · Cited by 271
Self-citation
Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance
Xiao, H., Zheng, Y., Ma, L., Tian, L., & Sun, Q. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.648407 · Cited by 264
DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical application
Hu, C., Liu, X., Zeng, Y., Liu, J., & Wu, F. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01154-x · Cited by 268
Self-citation
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine
Turcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240
Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment
van Zyl, B., Tang, D., & Bowden, N. A. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0336 · Cited by 234
Chemoresistance and targeted therapies in ovarian and endometrial cancers
Brasseur, K., Gévry, N. Y., & Asselin, É. (2016) · Oncotarget · doi:10.18632/oncotarget.14021 · Cited by 230
MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine
Xiang, Y., Ma, N., Wang, D., Zhang, Y., Zhou, J., Wu, G., Zhao, R., Huang, H., Wang, X., Qiao, Y., et al. (2013) · Oncogene · doi:10.1038/onc.2012.575 · Cited by 227
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Zhang, H., Pandey, S., Travers, M. E., Sun, H., Morton, G. C., Madžo, J., Chung, W., Khowsathit, J., Pérez, Ó. C., Barrero, C. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.051 · Cited by 223
Epigenetic treatment of solid tumours: a review of clinical trials
Nervi, C., Marinis, E. D., & Codacci-Pisanelli, G. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0157-2 · Cited by 215
DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine
Yu, J., Qin, B., Moyer, A. M., Nowsheen, S., Liu, T., Qin, S., Zhuang, Y., Liu, D., Lu, W., Kalari, K. R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97924 · Cited by 203
Lactate‐induced protein lactylation: A bridge between epigenetics and metabolic reprogramming in cancer
Wang, T., Zeng, Y., Li, Z., Jing, D., Fan, G., Liu, M., Zhuo, Q., Ji, S., Yu, X., Xu, X., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13478 · Cited by 207
Self-citation
Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
Odunsi, K. O., Matsuzaki, J., James, S. R., Mhawech-Fauceglia, P. Y., Tsuji, T., Miller, A., Zhang, W., Akers, S. N., Griffiths, E. A., Miliotto, A. J., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0126 · Cited by 193
The role of ABC transporters in ovarian cancer progression and chemoresistance
Ween, M. P., Armstrong, M., Oehler, M. K., & Ricciardelli, C. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.05.012 · Cited by 188
Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives
Yousuf, I., Bashir, M., Arjmand, F., & Tabassum, S. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214104 · Cited by 167
TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells
Cárdenas, H., Vieth, E., Lee, J., Segar, M. W., Liu, Y., Nephew, K. P., & Matei, D. E. (2014) · Epigenetics · doi:10.4161/15592294.2014.971608 · Cited by 166
Self-citation
Combining epigenetic and immune therapy to overcome cancer resistance
Gomez, S., Tabernacki, T., Kobyra, J. A., Roberts, P. A., & Chiappinelli, K. B. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.019 · Cited by 170
DNA Hypomethylating Drugs in Cancer TherapyPreprint
Sato, T., Issa, J. J., & Kropf, P. L. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026948 · Cited by 169
Epigenetic Targeting of Ovarian Cancer Stem Cells
Wang, Y., Cárdenas, H., Fang, F., Condello, S., Taverna, P., Segar, M. W., Liu, Y., Nephew, K. P., & Matei, D. E. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1022 · Cited by 161
Self-citation
Harnessing the potential of epigenetic therapy to target solid tumors
Ahuja, N., Easwaran, H., & Baylin, S. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69736 · Cited by 165
Epigenetic mechanisms of importance for drug treatment
Ivanov, M., Barragán, I., & Ingelman‐Sundberg, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.05.004 · Cited by 161
Clinical and biological effects of demethylating agents on solid tumours – A systematic review
Linnekamp, J. F., Butter, R., Spijker, R., Medema, J. P., & van Laarhoven, H. W. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.004 · Cited by 159
Cancer epigenetics drug discovery and development: the challenge of hitting the mark
Campbell, R. M., & Tummino, P. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71605 · Cited by 157
Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
Sadida, H. Q., Abdulla, A., Marzooqi, S. A., Hashem, S., Macha, M. A., Akil, A. S. A.-S., & Bhat, A. A. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101821 · Cited by 151
Epigenetic polypharmacology: from combination therapy to multitargeted drugs
de Lera, Á. R., & Ganesan, A. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0271-9 · Cited by 154
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yokoyama, Y., Zhu, H., Lee, J., Kossenkov, A. V., Wu, S. Y., Wickramasinghe, J. M., Yin, X., Palozola, K. C., Gardini, A., Showe, L. C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0854 · Cited by 144
DNA methylation as a transcriptional regulator of the immune system
Morales‐Nebreda, L., McLafferty, F. S., & Singer, B. D. (2018) · Translational research · doi:10.1016/j.trsl.2018.08.001 · Cited by 141
Nucleosidic DNA demethylating epigenetic drugs – A comprehensive review from discovery to clinic
Agrawal, K., Das, V., Vyas, P., & Hajdúch, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.006 · Cited by 141
Epigenetic programming, early life nutrition and the risk of metabolic disease
Block, T., & El-Osta, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.09.003 · Cited by 130
An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
Pulliam, N., Fang, F., Özeş, A., Tang, J., Adewuyi, A., Keer, H. N., Lyons, J. F., Baylin, S. B., Matei, D. E., Nakshatri, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0204 · Cited by 126
Self-citation
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
Glasspool, R. M., Brown, R. E., Gore, M. E., Rustin, G. J. S., McNeish, I. A., Wilson, R. H., Pledge, S., Paul, J., Mackean, M., Hall, G. D., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.116 · Cited by 125
Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
Moufarrij, S., Srivastava, A., Gomez, S., Hadley, M. M., Palmer, E., Austin, P. T., Chisholm, S., Diab, N., Roche, K. C., Yu, A. Y. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-60409-4 · Cited by 119
IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells
Wang, Y., Zong, X., Mitra, S., Mitra, A. K., Matei, D. E., & Nephew, K. P. (2018) · JCI Insight · doi:10.1172/jci.insight.122360 · Cited by 116
Self-citation
The mismatch repair-dependent DNA damage response: Mechanisms and implications
Gupta, D., & Heinen, C. D. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.03.009 · Cited by 117
Epigenomes as therapeutic targets
Hamm, C. A., & Costa, F. F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.03.003 · Cited by 114
Effects of 5-Aza-2′-deoxycytidine (decitabine) on gene expression
Seelan, R. S., Mukhopadhyay, P., Pisano, M., & Greene, R. M. (2018) · Drug Metabolism Reviews · doi:10.1080/03602532.2018.1437446 · Cited by 118
Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer
Zhang, Y., Zheng, Y., Wang, J., Lu, X., Wang, Z., Chen, L., Guan, X., & Tong, J. (2014) · Epigenetics · doi:10.4161/epi.28601 · Cited by 112
DNMT Inhibitors Increase Methylation in the Cancer Genome
Giri, A. K., & Aittokallio, T. A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00385 · Cited by 111
Epigenetic therapy in gastrointestinal cancer: the right combination
Abdelfatah, E., Kerner, Z. J., Nanda, N., & Ahuja, N. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644247 · Cited by 115
Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs
Fang, F., Cárdenas, H., Huang, H., Jiang, G., Perkins, S. M., Zhang, C., Keer, H. N., Liu, Y., Nephew, K. P., & Matei, D. E. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1492 · Cited by 110
Self-citation
Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors
Nie, J., Liu, L., Li, X., & Han, W. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.08.010 · Cited by 105
Epithelial Mutations in Endometriosis: Link to Ovarian Cancer
Bulun, S. E., Wan, Y., & Matei, D. E. (2019) · Endocrinology · doi:10.1210/en.2018-00794 · Cited by 105
Self-citation
The role of aberrant DNA methylation in cancer initiation and clinical impacts
Geissler, F., Nesic, K., Kondrashova, O., Dobrovic, A., Swisher, E. M., Scott, C. L., & Wakefield, M. J. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231220511 · Cited by 112
Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells
Siebenkäs, C., Chiappinelli, K. B., Guzzetta, A. A., Sharma, A. R., Jeschke, J., Vatapalli, R. J., Baylin, S. B., & Ahuja, N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179501 · Cited by 100
The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer
Fang, F., Munck, J. M., Tang, J., Taverna, P., Wang, Y., Miller, D. F., Pilrose, J. M., Choy, G. S., Azab, M., Pawelczak, K. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1553 · Cited by 97
Self-citation
Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer
Tucker, D. W., Getchell, C. R., McCarthy, E. T., Öhman, A., Sasamoto, N., Xu, S., Ko, J. Y., Gupta, M., Shafrir, A. L., Medina, J. E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1958 · Cited by 97
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer
Oza, A. M., Matulonis, U. A., Secord, A. A., Nemunaitis, J. J., Roman, L. D., Blagden, S. P., Banerjee, S. N., McGuire, W. P., Ghamande, S. A., Birrer, M. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1638 · Cited by 93
Self-citation
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
Reid, T. R., Oronsky, B. T., Scicinski, J. J., Scribner, C. L., Knox, S. J., Ning, S., Peehl, D. M., Korn, R. L., Stirn, M., Carter, C. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00089-3 · Cited by 92
Ovarian cancer stem cells: Are they real and why are they important?
Shah, M. M., & Landen, C. N. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.12.001 · Cited by 89
Addressing intra-tumoral heterogeneity and therapy resistance
Rybinski, B., & Yun, K. (2016) · Oncotarget · doi:10.18632/oncotarget.11875 · Cited by 95
Cell signaling and cancer: a mechanistic insight into drug resistance
Panda, M., & Biswal, B. K. (2019) · Molecular Biology Reports · doi:10.1007/s11033-019-04958-6 · Cited by 89
Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study
Azad, N. S., El-Khoueiry, A. B., Yin, J., Oberg, A. L., Flynn, P. J., Adkins, D., Sharma, A. R., Weisenberger, D. J., Brown, T. D., Medvari, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15108 · Cited by 88
The Roles of DNA Methylation in the Stages of Cancer
McMahon, K. W., Karunasena, E., & Ahuja, N. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000279 · Cited by 88
Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation
Zahnow, C. A., Topper, M. J., Stone, M. L., Stewart, T. M., Li, H., Baylin, S. B., & Casero, R. A. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.007 · Cited by 88
Epigenomic heterogeneity as a source of tumour evolution
Laisné, M., Lupien, M., & Vallot, C. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00757-9 · Cited by 93
Green tea polyphenol EGCG reverse cisplatin resistance of A549/DDP cell line through candidate genes demethylation
Zhang, Y., Wang, X., Han, L., Zhou, Y., & Sun, S. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.12.016 · Cited by 83
DNA Methylation: From Cancer Biology to Clinical Perspectives
Chen, C., Wang, Z., Ding, Y., Wang, L., Wang, S., Wang, H., & Qin, Y. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2712326 · Cited by 89
Combination of chemotherapy and cancer stem cell targeting agents: Preclinical and clinical studies
Li, Y., Atkinson, K., & Zhang, T. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.03.008 · Cited by 80
Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma
Mohan, D. R., Lerário, A. M., Else, T., Mukherjee, B., Almeida, M. Q., Vinco, M., Rege, J., Mariani, B. M. P., Zerbini, M. C. N., Mendonca, B. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2693 · Cited by 84
Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts
Srivastava, P., Paluch, B. E., Matsuzaki, J., James, S. R., Collamat, G., Taverna, P., Karpf, A. R., & Griffiths, E. A. (2015) · Epigenetics · doi:10.1080/15592294.2015.1017198 · Cited by 81
Cancer Epigenetics: New Therapies and New Challenges
Hatzimichael, E. C., & Crook, T. (2013) · Journal of Drug Delivery · doi:10.1155/2013/529312 · Cited by 85
Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions
Alkema, N. G., Wisman, G. B. A., van der Zee, A. G. J., van Vugt, M. A. T. M., & de Jong, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.005 · Cited by 84
Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer
Leon, M. D., Cárdenas, H., Vieth, E., Emerson, R. E., Segar, M. W., Liu, Y., Nephew, K. P., & Matei, D. E. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.06.017 · Cited by 79
Self-citation
Novel Strategies for Cancer Treatment: Highlights from the 55th IACR Annual Conference
Charmsaz, S., Collins, D. M., Perry, A. S., & Prencipe, M. (2019) · Cancers · doi:10.3390/cancers11081125 · Cited by 77
Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer
Chen, S., Xie, P., Cowan, M. L., Huang, H., Cárdenas, H., Keathley, R., Tanner, E. J., Fleming, G. F., Moroney, J. W., Pant, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158800 · Cited by 78
Self-citation
SGI-110. DNA methyltransferase inhibitor, Oncolytic
Griffiths, E. A., Choy, G. S., Redkar, S., Taverna, P., Azab, M., & Karpf, A. R. (2013) · Drugs of the Future · doi:10.1358/dof.2013.38.8.1980499 · Cited by 76
Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine
Albany, C., Hever-Jardine, M. P., von Herrmann, K. M., Yim, C. Y., Tam, J. K. V., Warzecha, J. M., Shin, L., Bock, S. E., Curran, B. S., Chaudhry, A. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13811 · Cited by 74
Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients
Liao, Y.-P., Chen, L.-Y., Huang, R., Su, P., Chan, M. W. Y., Chang, C., Yu, M., Wang, P., Yen, M.-S., Nephew, K. P., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt583 · Cited by 71
Self-citation
RASSF1Apromoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA
Giannopoulou, L., Chebouti, I., Pavlakis, K., Kasimir‐Bauer, S., & Lianidou, E. S. (2017) · Oncotarget · doi:10.18632/oncotarget.15249 · Cited by 74
Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside
Sarno, F., Benincasa, G., List, M., Barabási, A.-L., Baumbach, J., Ciardiello, F., Filetti, S., Glass, K., Loscalzo, J., Marchese, C., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01047-z · Cited by 78
Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma
Liu, Y., Wang, C., Li, X., Dong, L., Yang, Q., Chen, M., Shi, F., Brock, M. V., Liu, M., Mei, Q., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002347 · Cited by 72
Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes
Matei, D. E., & Nephew, K. P. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3837 · Cited by 71
Self-citation
Epigenetic Therapy for Solid Tumors: from Bench Science to Clinical Trials
Juo, Y.-Y., Gong, X.-J., Mishra, A., Cui, X. X., Baylin, S. B., Azad, N. S., & Ahuja, N. (2015) · Epigenomics · doi:10.2217/epi.14.73 · Cited by 72
5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor Cells
Oing, C., Verem, I., Mansour, W. Y., Bokemeyer, C., Dyshlovoy, S. A., & Honecker, F. U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010021 · Cited by 68
RETRACTED ARTICLE: An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer
Janzen, D. M., Tiourin, E., Salehi, J. A., Paik, D. Y., Lu, J. N., Pellegrini, M. A., & Memarzadeh, S. (2015) · Nature Communications · doi:10.1038/ncomms8956 · Cited by 69
Retracted
Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases
Vendetti, F. P., & Rudin, C. M. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.819337 · Cited by 68
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells
Simpkins, F., Jang, K., Yoon, H., Hew, K. E., Kim, M., Azzam, D. J., Sun, J., Zhao, D., Ince, T. A., Liu, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3697 · Cited by 67
Biology-driven therapy advances in high-grade serous ovarian cancer
Wang, Y., Duval, A. J., Adli, M., & Matei, D. E. (2024) · Journal of Clinical Investigation · doi:10.1172/jci174013 · Cited by 74
Self-citation
Environmental Epigenetics: Crossroad between Public Health, Lifestyle, and Cancer Prevention
Romani, M., Pistillo, M. P., & Banelli, B. (2015) · BioMed Research International · doi:10.1155/2015/587983 · Cited by 71
Epigenetic mechanisms and therapeutic targets of chemotherapy resistance in epithelial ovarian cancer
Borley, J., & Brown, R. E. (2015) · Annals of Medicine · doi:10.3109/07853890.2015.1043140 · Cited by 67

Authors: Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., Berry, W. A., Huang, T., & Nephew, K. P.
Affiliations: Indiana University Health (US)
Corresponding author: Matei, Daniela
Nephew, Kenneth P.
ORCID: Matei, Daniela
Fang, Fang
Shen, Changyu
Schilder, Jeanne
Zeng, Yan
Berry, William A.
Huang, Tim
Nephew, Kenneth P.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2012-04-30
Volume: 72
Issue: 9
Pages: 2197-2205
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-11-3909
PMC: PMC3700422
OpenAlex: W2151783390
Cited by: 390
References: 56
Citations by year: 2026: 20 · 2025: 11 · 2024: 27 · 2023: 23 · 2022: 21 · 2021: 33 · 2020: 21 · 2019: 38 · 2018: 36 · 2017: 33 · 2016: 35 · 2015: 39 · 2014: 32 · 2013: 18 · 2012: 3
FWCI: 34.25
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
IUScholarWorks (Indiana University) (submittedVersion)
Funders: U.S. Food and Drug Administration
National Cancer Institute (CA113001, R21CA133877, R01CA085289, U54CA113001, CA133877)
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords: ovarian cancer, platinum resistance, decitabine, DNA demethylation, hypomethylating agents, carboplatin, progression-free survival, MLH1, RASSF1A, HOXA10, HOXA11, drug transporters, Wnt signaling, apoptosis, cytokine signaling pathways
MeSH terms: Decitabine, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Peritoneal Neoplasms, Carboplatin, Disease-Free Survival, DNA Methylation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epigenetic Resensitization to Platinum in Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks